###begin article-title 0
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with insulin-dependent diabetes or coronary heart disease following rehabilitation express serum fractalkine levels similar to those in healthy control subjects
###end article-title 0
###begin p 1
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 609 610 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 696 697 690 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 777 778 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1087 1095 1081 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 308 316 <span type="species:ncbi:9606">patients</span>
###xml 385 393 <span type="species:ncbi:9606">patients</span>
###xml 395 399 <span type="species:ncbi:9606">IDDM</span>
###xml 538 546 <span type="species:ncbi:9606">patients</span>
###xml 662 666 <span type="species:ncbi:9606">IDDM</span>
###xml 667 675 <span type="species:ncbi:9606">patients</span>
###xml 750 754 <span type="species:ncbi:9606">IDDM</span>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
###xml 1020 1028 <span type="species:ncbi:9606">patients</span>
###xml 1229 1237 <span type="species:ncbi:9606">patients</span>
The chemokine and adhesion molecule fractalkine and its receptor CX3CR1 have emerged as interesting regulators in inflammation and related atherosclerosis. The pro-inflammatory status may be counteracted by appropriate treatment, such as in rehabilitation. We compared serum fractalkine concentrations of 46 patients with coronary heart disease (CHD) and 47 insulin-dependent diabetic patients (IDDM) following rehabilitation with those of 50 control subjects. Following rehabilitation serum fractalkine levels (477 +/- 225 pg/mL) in CHD patients were similar to those in control subjects (572 +/- 205 pg/mL; P = 0.303), whereas fractalkine levels were lower in IDDM patients (430 +/- 256 pg/mL; P = 0.042). No significant difference between CHD and IDDM patients was present (P = 0.319). Postprandial hyperlipemia may influence inflammation; thus, we investigated fractalkine levels four and eight hours after inducing postprandial hyperlipemia. However, we did not find any significant alterations in CHD and diabetic patients, whereas the fractalkine levels in controls were reduced. In vitro, lipofundin used as a hyperlipemic stimulus was added to vessel wall cells and reduced fractalkine levels. Low fractalkine levels in patients attending rehabilitation indicate a beneficial effect of the rehabilitation procedure on innate inflammatory pathways, such as the chemokine and adhesion molecule fractalkine.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-vhrm-5-849">1</xref>
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-vhrm-5-849">2</xref>
###xml 221 222 221 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-vhrm-5-849">3</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-vhrm-5-849">4</xref>
###xml 397 398 397 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-vhrm-5-849">5</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-vhrm-5-849">6</xref>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-5-849">7</xref>
###xml 827 828 827 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-vhrm-5-849">8</xref>
###xml 1068 1069 1068 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-vhrm-5-849">8</xref>
###xml 1070 1071 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-vhrm-5-849">9</xref>
Atherosclerosis is a multifactorial disease of the blood vessel wall that is strongly influenced by inflammatory pathways,1,2 such as adhesion of leukocytes to the endothelium, and other inflammatory or innate mechanisms.3,4 During atherogenesis, monocytes accumulate in the neointima and subsequently transform into tissue macrophages/foam cells. In addition, other leukocytes, such as mast cells5 or T-cells,6 are also found in atherosclerotic lesions. The invasion of the vessel wall starts when blood cells adhere to the endothelium. However, the mechanisms underlying the initial activation have still not been completely defined. The leukocyte-endothelial interaction involves rolling, firm adhesion, and migration into the neointima, which is mediated by selectins and other adhesion molecules7 as well as by chemokines.8 Chemokines attract and direct cells along a chemotactic gradient. Furthermore, they may activate other atherosclerosis-relevant functions of vessel wall cells or leukocytes, for example, by activating adhesion molecules on the endothelium.8,9
###end p 3
###begin p 4
###xml 45 47 45 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-vhrm-5-849">10</xref>
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-vhrm-5-849">11</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-vhrm-5-849">15</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-vhrm-5-849">16</xref>
###xml 587 588 587 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-vhrm-5-849">17</xref>
###xml 970 971 970 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1184 1186 1184 1186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-vhrm-5-849">18</xref>
The recently discovered chemokine fractalkine10 and its receptor CX3CR1 have emerged as interesting intermediaries in atherosclerosis. Fractalkine is a multidomain protein expressed on the surface of a variety of cells, including activated endothelial and smooth muscle cells.11-15 Fractalkine exhibits features which have not been described for other members of the chemokine family, including its exceptionally large size of 95 kDa and the presence of a transmembrane anchor. Furthermore, a soluble form can be released from its membrane-associated form by extracellular cleavage.16 CX3CR1 is a seven-transmembrane-spanning fractalkine receptor, mediating its signal by G-proteins, as most cytokines do. This receptor mediates the firm adhesion to fractalkine even in the absence of G-protein activation17 and thus plays a role as an adhesion molecule in addition to functioning as a chemokine. In this way, membrane-bound fractalkine contributes to the adhesion of CX3CR1-expressing leukocytes. On the other hand, soluble fractalkine, after enzymatic cleavage and release, has potent chemotactic activity for monocytes and lymphocytes but, like CC chemokines, not for granulocytes.18
###end p 4
###begin p 5
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-vhrm-5-849">4</xref>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-vhrm-5-849">7</xref>
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-vhrm-5-849">8</xref>
###xml 445 446 441 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 499 501 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-vhrm-5-849">19</xref>
###xml 896 898 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-vhrm-5-849">20</xref>
###xml 992 994 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-vhrm-5-849">21</xref>
###xml 1114 1116 1108 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 1124 1125 1118 1119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1219 1220 1213 1214 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1391 1393 1385 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-vhrm-5-849">23</xref>
###xml 1394 1396 1388 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-vhrm-5-849">24</xref>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 361 367 <span type="species:ncbi:10090">murine</span>
###xml 734 742 <span type="species:ncbi:9606">patients</span>
###xml 786 794 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:9606">patients</span>
###xml 1156 1164 <span type="species:ncbi:9606">patients</span>
Cytokines, including chemokines, and other innate compounds are strongly involved in the inflammatory pathways contributing to atherosclerosis.4,7,8 Thus, evidence has been provided that fractalkine plays a role in various cardiovascular diseases. For example, increased fractalkine levels have been reported in patients after cardiac allograft rejection. In a murine model, allograft survival was prolonged from 7 +/- 1 days to 49 +/- 30 days (P </= 0.0008) by administering fractalkine antibodies.19 These studies identified a critical role for fractalkine in the pathogenesis of acute rejection and suggest that fractalkine inhibition might be a potential therapeutic target. Fractalkine levels have only been rarely determined in patients; however, it has been shown that Alzheimer patients express enhanced fractalkine levels, correlating with the Mini-Mental State Examination (MMSE) score.20 Another study also reported that fractalkine levels are enhanced in Wegener's granulomatosis.21 In patients with coronary artery disease fractalkine plasma levels were enhanced and then reduced after statin therapy.22 When CX3CR1 genotypes were analyzed in patients with acute coronary syndromes and healthy controls, CX3CR1-I249 heterozygosity was associated with a markedly reduced risk of acute coronary events, independent of established coronary risk factors such as smoking or diabetes.23,24
###end p 5
###begin p 6
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-vhrm-5-849">25</xref>
###xml 818 820 818 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-vhrm-5-849">26</xref>
###xml 821 823 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-vhrm-5-849">27</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-vhrm-5-849">28</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
###xml 994 998 <span type="species:ncbi:10116">rats</span>
Both the risk and the rate of development of atherosclerosis are increased in diabetic patients, but the underlying mechanisms are still not completely understood. Epidemiologic and pathophysiologic evidence suggests that lipoproteins, platelets, or soluble clotting factors represent contributing factors. Furthermore, both balance of the prostaglandin-metabolites prostacycline and thromboxane and blood pressure regulation are disturbed. On the other hand, the metabolism and proliferation of arterial smooth muscle cells are modified.25 Many of these alterations accompany hyperinsulinemia and may account for the recent evidence that hyperinsulinemia is a risk factor for atherosclerosis. Cytokines and chemokines may contribute to regulate atherosclerosis-related pathways in diabetes or its associated diseases.26,27 However, little is known about the expression of fractalkine and its receptor in diabetes, although the mRNA of fractalkine and its receptor were upregulated in diabetic rats in the early stages of diabetic nephropathy.28
###end p 6
###begin p 7
###xml 600 602 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
To the best of our knowledge, fractalkine levels have not yet been analyzed in patients with insulin-dependent diabetes following rehabilitation. An optimized medical treatment consisting of medication such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARBs), and statins plays an important role during rehabilitation. Some of the aforementioned drugs may also exert anti-inflammatory properties, which could contribute to their beneficial effects. Indeed, fractalkine levels were reduced in patients with coronary artery disease after a six-week statin treatment.22 Thus, rehabilitation may normalize levels of fractalkine.
###end p 7
###begin p 8
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-vhrm-5-849">29</xref>
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-vhrm-5-849">30</xref>
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-vhrm-5-849">31</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-vhrm-5-849">32</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-vhrm-5-849">33</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-vhrm-5-849">34</xref>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
###xml 639 647 <span type="species:ncbi:9606">patients</span>
In diabetic patients postprandial hyperlipemia may represent a potential risk factor for atherosclerosis.29 Postprandial hyperlipemia can induce an inflammatory state by activating granulocytes,30 leukocytes,31 or endothelial cells.32 Triglyceride-rich lipids (TRL) may even penetrate the arterial wall and activate vascular smooth muscle cell genes differently, depending on the composition (ie, butter, vegetable oil/fish oil, or olive oil) of the lipid.33 Furthermore, chylomicron remnants containing TRLs have been shown to potently activate smooth muscle cell MCP-1 production.34 Postprandial hyperlipemia may promote inflammation in patients and oppose therapy. However, it is not clear whether therapy during rehabilitation may prevent postprandial hyperlipemia from inducing inflammation.
###end p 8
###begin p 9
###xml 615 623 615 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 129 137 <span type="species:ncbi:9606">patients</span>
###xml 362 370 <span type="species:ncbi:9606">patients</span>
###xml 769 777 <span type="species:ncbi:9606">patients</span>
Thus, in the present study we investigated the expression of serum fractalkine in patients with coronary heart disease (CHD) and patients with insulin-dependent diabetes following optimized medical treatment after a period of rehabilitation. Subsequently, we analyzed the effect of postprandial hyperlipemia. We found that fractalkine levels in CHD and diabetic patients after rehabilitation were comparable to those in control subjects and that the postprandial fractalkine levels were not significantly increased. However, postprandial fractalkine levels in control subjects were reduced, a finding paralleled by in vitro cell culture data. These data indicate that the anti-inflammatory effects of the rehabilitation medication played an important role in the study patients.
###end p 9
###begin title 10
Material and methods
###end title 10
###begin title 11
Study population
###end title 11
###begin p 12
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 155 159 <span type="species:ncbi:9606">IDDM</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
We determined the serum concentrations of fractalkine in 46 nondiabetic patients with angiographically proven CHD, 47 insulin-dependent diabetic patients (IDDM), and 50 healthy controls. The patients were recruited in the "Curschmann Klinik fur Rehabilitation" (Timmendorfer Strand/Germany). The control subjects were volunteers (mostly working at the Curschmann Clinic) with no prove of CHD or diabetes mellitus. The study was approved by the ethics committee of the University of Lubeck, Schleswig Holstein, Germany. All patients gave written informed consent.
###end p 12
###begin title 13
Blood sampling and clinical laboratory parameters
###end title 13
###begin p 14
Blood samples were taken from all subjects under standardized conditions after an overnight period of fasting (time-zz [compared below]). The next blood samples were taken four and eight hours later. All blood samples were immediately centrifuged at 4,000 rpm for 10 minutes, supernatants were extracted and divided into aliquots. All aliquots were stored at -80 degreesC until analysis. The fractalkine levels in the samples were measured by using a sandwich ELISA (enzyme-linked immunosorbent assay; DuoSet, R&D Systems, Wiesbaden, Germany) according to the manufacturer's recommendations. Besides fractalkine, atherosclerosis-relevant serum markers of inflammation (C-reactive protein [CRP]) and lipid metabolism (low-density lipoprotein cholesterol [LDL-C]; high-density lipoprotein cholesterol [HDL-C]; total cholesterol [TC]; and triglycerides [TG]) were measured. The lipid markers were routinely determined by standard clinical laboratory analysis.
###end p 14
###begin title 15
Induction of postprandial hyperlipemia
###end title 15
###begin p 16
###xml 126 127 126 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 490 498 <span type="species:ncbi:9606">patients</span>
Postprandial hyperlipemia was induced by eating a high calorie fatty meal. Briefly, the meal contained a total of 1,265 kcal/m2 body surface area. It was composed of 105 g fat (consisting of approximately 52 g saturated fat, 53 g unsaturated fat, and 300 mg cholesterol), 48 g carbohydrates, and 32 g protein. Probands were instructed to eat the meal within 15 minutes and not to eat any other food until the subsequent blood samples were taken. Before the meal (time-point 0) the diabetic patients received a dose of insulin subcutaneously, which was individually adapted to the meal described above. Glucose levels were measured every two hours until the end of the study period in order to prevent severe hypo- or hyperglycemia. All glucose levels were in an acceptable range; thus, no glucose or further insulin administration was required until the end of the eight-hour study period.
###end p 16
###begin title 17
###xml 25 30 <span type="species:ncbi:9606">human</span>
Isolation and culture of human vascular vessel wall cells
###end title 17
###begin p 18
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-vhrm-5-849">35</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-vhrm-5-849">36</xref>
###xml 381 382 381 382 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 707 715 701 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-vhrm-5-849">Figure 3</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 340 344 <span type="species:ncbi:9913">calf</span>
Human vascular smooth muscle cells were isolated from unused portions of saphenous veins obtained following bypass surgery, as described previously.35,36 Use of the specimens that would otherwise have been discarded was approved by the local ethics committee. Dulbecco's modified Eagle's medium (DMEM; 1 g/L D-glucose) containing 10% fetal calf serum (FCS), 1% antibiotics, and 1% l-glutamine (DMEM medium) was used for cell culture. Upon confluency the cells were subcultured after treatment with trypsin/EDTA (0.05% 0.02%, 10 minutes, 37 degreesC, Biochrom, Berlin, Germany). We used smooth muscle cells in passages 4 to 7. Stimulation experiments were performed in 24-well culture plates as specified in Figure 3. Lipofundin LCT-10 solution was obtained from Braun (Melsungen, Germany).
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS Inc, Chicago, IL, USA). Continuous variables were compared by ANOVA. Chi-squared test was used for categorical variables. Correlation analysis was conducted according to the Pearson method.
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
Baseline characteristics
###end title 22
###begin p 23
###xml 64 71 64 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1-vhrm-5-849">Table 1</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 126 130 <span type="species:ncbi:9606">IDDM</span>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 334 341 <span type="species:ncbi:9606">patient</span>
###xml 448 455 <span type="species:ncbi:9606">patient</span>
###xml 589 596 <span type="species:ncbi:9606">patient</span>
###xml 664 671 <span type="species:ncbi:9606">patient</span>
The demographic data for the study populations are presented in Table 1. Compared with CHD patients and control subjects, the IDDM patients were older. The BMI was not significantly different, and the distribution of sexes was similar among the three groups. More smokers were found among the healthy control subjects than in the two patient groups. On the other hand, more subjects with hypertension or a family history of CHD were present in the patient groups. As anticipated, medical treatment with statins, beta-blockers, ACE inhibitors, ARBs, and diuretics was more prevalent in the patient groups. Except for diuretics, medication was similar in the tested patient groups. Healthy controls did not suffer from any obvious atherosclerotic, metabolic, or inflammatory disease.
###end p 23
###begin title 24
###xml 35 43 <span type="species:ncbi:9606">patients</span>
The fractalkine levels in diabetic patients are lower than in healthy control subjects
###end title 24
###begin p 25
###xml 474 482 474 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-vhrm-5-849">Figure 1</xref>
###xml 659 660 655 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 758 759 752 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 870 871 864 865 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
###xml 148 152 <span type="species:ncbi:9606">IDDM</span>
###xml 161 169 <span type="species:ncbi:9606">patients</span>
###xml 284 292 <span type="species:ncbi:9606">patients</span>
###xml 391 395 <span type="species:ncbi:9606">IDDM</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
###xml 703 707 <span type="species:ncbi:9606">IDDM</span>
###xml 708 716 <span type="species:ncbi:9606">patients</span>
###xml 847 855 <span type="species:ncbi:9606">patients</span>
###xml 857 861 <span type="species:ncbi:9606">IDDM</span>
###xml 915 922 <span type="species:ncbi:9606">patient</span>
Fractalkine levels have not been measured yet in diabetic patients following rehabilitation. Thus, we analyzed the expression of fractalkine in the IDDM and CHD patients who received optimal medical treatment and underwent rehabilitation for four weeks. The fractalkine levels of the patients were compared to those of the control subjects. A comparison of the fractalkine levels in CHD and IDDM patients after rehabilitation and healthy controls (time-point 0) is shown in Figure 1. At this time-point fractalkine levels were slightly but not statistically significantly lower in CHD patients (477 +/- 225 pg/ml) than in control subjects (527 +/- 205 pg/ml; P = 0.303). In contrast, they were lower in IDDM patients than in the controls (430 +/- 256 pg/ml; P = 0.042), whereas they were not significantly different from fractalkine levels in CHD patients (IDDM vs CHD; P = 0.319). Thus, fractalkine levels in both patient groups were below or equal to control levels.
###end p 25
###begin title 26
###xml 64 68 <span type="species:ncbi:9606">IDDM</span>
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Postprandial hyperlipemia does not reduce fractalkine levels in IDDM and CHD patients
###end title 26
###begin p 27
###xml 613 614 609 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 702 710 696 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-vhrm-5-849">Figure 2</xref>
###xml 1106 1107 1094 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1230 1231 1218 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1259 1260 1247 1248 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1484 1485 1472 1473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1498 1499 1486 1487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1678 1679 1666 1667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1994 2002 1982 1990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2220 2228 2208 2216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-vhrm-5-849">Figure 3</xref>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 543 551 <span type="species:ncbi:9606">patients</span>
###xml 584 592 <span type="species:ncbi:9606">patients</span>
###xml 818 822 <span type="species:ncbi:9606">IDDM</span>
###xml 1392 1396 <span type="species:ncbi:9606">IDDM</span>
###xml 1405 1413 <span type="species:ncbi:9606">patients</span>
###xml 1619 1623 <span type="species:ncbi:9606">IDDM</span>
###xml 1837 1841 <span type="species:ncbi:9606">IDDM</span>
###xml 1842 1850 <span type="species:ncbi:9606">patients</span>
Hyperlipemia can activate inflammatory pathways. However, it was unclear whether postprandial hyperlipemia affects inflammatory parameters in rehabilitation patients as compared to control subjects. Thus, after the first blood sample was taken (time-point 0), a defined postprandial hyperlipemia was induced in the three investigated groups. Four and eight hours after the first blood sampling and eating the defined meal the next samples were taken (time-point 4; time-point 8). At time-point 4 the fractalkine levels were higher in diabetic patients (548 +/- 300 pg/mL) than in CHD patients (437 +/- 228 pg/mL; P = 0.033); however, they were not different from the control levels (474 +/- 203 pg/mL; Figure 2). At time-point 8 the fractalkine levels were 432 +/- 212 pg/mL in the CHD group, 454 +/- 262 pg/mL in the IDDM group, and 393 +/- 166 pg/ml in the control group. These values were not significantly different from each other. Comparing each group at the different time-points by ANOVA revealed that only the differences in the values for healthy control subjects were statistically significant (P = 0.004). Post hoc analysis showed that the fractalkine levels at time-point 8 were different from those at time-point 4 (P = 0.046) and time-point 0 (P = 0.001), whereas at time-points 0 and 4 they were not significantly different. In contrast to control subjects, ANOVA analysis of IDDM and CHD patients did not reveal significant differences between the three time-points (P = 0.080 and P = 0.574, for diabetes and CHD, respectively). Post hoc analysis showed the same result at the 0.01 level. However, the IDDM time-points 0 and 4 were different at the 0.05 level (P = 0.033). Taken together, the data indicate that the fractalkine levels were only reduced in control subjects, whereas in CHD the levels remained low and in IDDM patients the levels fluctuated, although the differences were not significant according to ANOVA. In order to investigate the influence of hyperlipemia in vitro we incubated vascular smooth muscle cells, which represent a potential source of fractalkine in atherogenesis, with several lipofundin concentrations. We observed a dose-dependent reduction in fractalkine production (Figure 3).
###end p 27
###begin title 28
The fractalkine levels in the tested subjects do not correlate with CRP and lipids
###end title 28
###begin p 29
###xml 79 86 79 86 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2-vhrm-5-849">Table 2</xref>
###xml 193 194 189 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 232 233 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 856 857 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 941 942 931 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1021 1022 1009 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1050 1051 1038 1039 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 131 139 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 350 354 <span type="species:ncbi:9606">IDDM</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
###xml 499 503 <span type="species:ncbi:9606">IDDM</span>
The analysis of inflammatory and lipid markers at time-point 0 is presented in Table 2. The CRP levels were higher in the diabetic patients (10 +/- 16 mg/L) than in CHD patients (6 +/- 7 mg/L; P = 0.025) and controls (2 +/- 3 mg/L; P </= 0.001). All lipid parameters were highest in the healthy control subjects. The differences between controls and IDDM patients were less pronounced than the differences between controls and CHD patients. These data indicate that the lipid-lowering aspect of the IDDM and CHD medication worked properly. The correlation analysis revealed that there was no significant correlation between fractalkine serum levels, CRP, the lipid markers, age, or body mass index (BMI). BMI did not correlate with cholesterol, triglycerides, or LDL either. On the other hand, and as expected, BMI inversely correlated with HDL-C (-0.264; P </= 0.001); the high CRP levels inversely correlated with high HDL levels (-0.242; P </= 0.001); and cholesterol levels correlated well with triglycerides (0.463; P < 0.001) and LDL-C (0.847; P </= 0.001).
###end p 29
###begin title 30
Fractalkine in coronary artery bypass graft surgery and multivessel disease
###end title 30
###begin p 31
###xml 527 528 523 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 871 872 861 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 147 155 <span type="species:ncbi:9606">patients</span>
###xml 243 251 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 570 578 <span type="species:ncbi:9606">patients</span>
###xml 802 810 <span type="species:ncbi:9606">patients</span>
Among the CHD patients the subgroup of patients who had currently received coronary artery bypass graft (CABG) surgery were analyzed because these patients express the highest pro-inflammatory state prior to rehabilitation. However, in the 14 patients of the CHD group who had received a CABG within two weeks before attending the "Curschmann Klinik fur Rehabilitation" (533 +/- 288 pg/mL), the fractalkine serum levels were not significantly different from those in the CHD patients not receiving a bypass (459 +/- 203 pg/mL; P = 0.349). In addition, a CHD subgroup of patients suffering from multivessel disease with either two (496 +/- 237 pg/mL) or three (429 +/- 215 pg/mL) stenosed coronary arteries did not express significantly increased fractalkine levels after rehabilitation, as compared to patients with only one (507 +/- 231 pg/mL) occluded coronary artery (P = 0.575).
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 818 826 818 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 330 338 <span type="species:ncbi:9606">patients</span>
###xml 351 355 <span type="species:ncbi:9606">IDDM</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 555 559 <span type="species:ncbi:9606">IDDM</span>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
###xml 943 951 <span type="species:ncbi:9606">patients</span>
###xml 1115 1123 <span type="species:ncbi:9606">patients</span>
Innate inflammatory pathways are important in atherogenesis. Chemokines and adhesion molecules contribute to this process. Disease-associated, enhanced levels of adhesion molecules, cytokines, or chemokines may be reduced after optimal medical treatment during rehabilitation. Thus, we compared the serum levels of fractalkine in patients with CHD or IDDM following rehabilitation with those in healthy control subjects. Furthermore, we investigated the relation between fractalkine and classical risk factors for atherosclerosis in patients with CHD and IDDM in a state of postprandial hyperlipemia. The data show that the fractalkine levels of the patients after rehabilitation were at the control level or lower. Postprandial hyperlipemia reduced the fractalkine levels in control subjects and in vessel wall cells in vitro, whereas postprandial hyperlipemia did not result in significantly different fractalkine levels in diabetic and CHF patients according to ANOVA. These data indicate that the fractalkine levels were similar to control values and that acute hyperlipemia did not alter fractalkine levels in patients, whereas it did so in controls.
###end p 33
###begin p 34
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-vhrm-5-849">37</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-vhrm-5-849">38</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 857 858 851 852 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 936 938 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-vhrm-5-849">28</xref>
###xml 994 995 988 989 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 159 164 <span type="species:ncbi:9606">human</span>
###xml 293 301 <span type="species:ncbi:9606">patients</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 726 734 <span type="species:ncbi:9606">patients</span>
###xml 812 818 <span type="species:ncbi:10090">murine</span>
###xml 931 935 <span type="species:ncbi:10116">rats</span>
###xml 1521 1529 <span type="species:ncbi:9606">patients</span>
###xml 1596 1604 <span type="species:ncbi:9606">patients</span>
###xml 1726 1734 <span type="species:ncbi:9606">patients</span>
###xml 1775 1782 <span type="species:ncbi:9606">patient</span>
Previous studies reported that soluble fractalkine was increased in CHD patients as compared to controls, and that membrane-bound fractalkine was increased in human carotid arteries and in animal models.37,38 In another study serum fractalkine levels were determined:22 These data showed that patients with unstable angina (1,199 +/- 112 pg/mL) had enhanced fractalkine levels as compared with control levels (423 +/- 25 pg/mL) and that six-month atorvastatin therapy, but not simvastatin therapy, greatly reduced the fractalkine levels in the investigated patients (587 +/- 89 pg/mL). These results are in line with the data shown in the present manuscript, which are in the range of those for the controls or statin-treated patients. Fractalkine has been demonstrated to be involved in diabetic nephropathy in murine models. Upregulated fractalkine and CX3CR1 levels were present in the early stage of diabetic kidney disease in rats.28 The aforementioned data suggest that fractalkine and CX3CR1 have an important role in the progression of diabetic nephropathy, functioning as an arrest chemokine in monocyte/macrophage adhesion before migration into the kidney. Blockade of the renin-angiotensin-aldosterone system and treatment with statins currently represent the only clinical strategies for treating the inflammatory process in diabetic nephropathy. Newer strategies include chemokine receptor antagonists and even immunosuppressive therapy, but these are still in the experimental stage. In contrast to the CHD patients, no data exist about the fractalkine levels in untreated diabetic patients. We are currently addressing this question. However, the cited data indicate that fractalkine levels are enhanced in CHD patients. The low fractalkine levels in the same patient group in the present study suggest an analogous reducing effect caused by 1) the rehabilitation process, and/or 2) alleviating the acute status of the disease.
###end p 34
###begin p 35
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39-vhrm-5-849">39</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40-vhrm-5-849">40</xref>
###xml 36 40 <span type="species:ncbi:9606">IDDM</span>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 211 219 <span type="species:ncbi:9606">patients</span>
###xml 372 380 <span type="species:ncbi:9606">patients</span>
Serum fractalkine levels in CHD and IDDM patients following rehabilitation did not differ from those in healthy control subjects. This may partly be explained by the optimal medical and lifestyle treatment that patients benefit from during rehabilitation. Thus, blood glucose, heart rate, and blood pressure are continuously monitored and promptly corrected. Furthermore, patients profit from physical activity and controlled food intake, ie, lifestyle improvement.39,40
###end p 35
###begin p 36
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41-vhrm-5-849">41</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-vhrm-5-849">42</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-vhrm-5-849">43</xref>
###xml 1120 1122 1120 1122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 1123 1125 1123 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41-vhrm-5-849">41</xref>
###xml 1376 1378 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-vhrm-5-849">42</xref>
###xml 1379 1381 1379 1381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-vhrm-5-849">43</xref>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
###xml 41 45 <span type="species:ncbi:9606">IDDM</span>
###xml 208 215 <span type="species:ncbi:9606">patient</span>
###xml 302 306 <span type="species:ncbi:9606">IDDM</span>
###xml 307 315 <span type="species:ncbi:9606">patients</span>
###xml 830 838 <span type="species:ncbi:9606">patients</span>
###xml 1444 1448 <span type="species:ncbi:9606">IDDM</span>
###xml 1449 1457 <span type="species:ncbi:9606">patients</span>
###xml 1566 1573 <span type="species:ncbi:9606">patient</span>
On the other hand, patients with CHD and IDDM in rehabilitation are no longer in an acute phase of the disease. The baseline characteristics of our study population indicate that medical treatment in the two patient groups was more prevalent than in control subjects. The majority (96%) of the CHD and IDDM patients were on statin therapy compared to only 4% in controls. In addition to their lipid-lowering activity, statins may also have anti-inflammatory effects. During the constrictive remodeling status, statins have the ability to stabilize the atherosclerotic plaque.41 In addition, their anti-inflammatory effect was measured by their ability to lower CRP levels.42,43 The lipid and CRP data in the latter publications are in line with those for the control population presented here. The lipid data in the present study patients also indicate that the treatment had a similarly beneficial effect. However, the CRP levels did not reach the control values, which might be explained by the type and dose of statins used in the current study. This may have influenced the expression of the inflammatory parameters.22,41 Other therapeutic agents in atherosclerotic diseases include ACE inhibitors and ARBs. Both agents can reduce the expression of angiotensin I and II receptors on endothelial cells and monocytes. Thereby, they may reduce various inflammatory processes.42,43 ACE inhibitors and ARB therapy was used in 72% of the CHD and IDDM patients, compared to only 10% among the healthy controls. We hypothesize that the low fractalkine levels in the two patient groups may be caused by the combined ACE inhibitor, ARB, and statin treatment.
###end p 36
###begin p 37
###xml 771 779 771 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 990 992 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-vhrm-5-849">30</xref>
###xml 993 995 993 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-vhrm-5-849">32</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-vhrm-5-849">44</xref>
###xml 1224 1226 1224 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45-vhrm-5-849">45</xref>
###xml 1227 1229 1227 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46-vhrm-5-849">46</xref>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
###xml 1075 1083 <span type="species:ncbi:9606">patients</span>
An approximate measure of treatment efficacy is shown by the differing responses to postprandial hyperlipemia found in the present experiments. Postprandial hyperlipemia significantly reduced fractalkine levels in the controls, whereas it had no effect in the patients. We assume that this lack of response was caused by the anti-inflammatory capacity of the drugs being used. On the other hand, the lower (systemic) fractalkine levels may reflect reduced shedding, which in turn may indicate enhanced vascular inflammation. However, this suggestion remains somewhat speculative since no corresponding data have been published. However, we found that lipid treatment (lipofundin) reduced fractalkine release in vascular smooth muscle cells in a dose-dependent fashion in in vitro experiments. The reduction in the fractalkine levels in the controls also indicates that the selected measurement time-points were adequate. Other reports used similar time-points for postprandial measurements.30,32 On the other hand, we found that cytokines could already be detected in bypass patients after three hours.44 The enhanced fractalkine level at the four-hour time-point may reflect activation of the inflammatory genes by insulin.45,46 However, insulin is also known to have anti-inflammatory effects.
###end p 37
###begin p 38
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 239 241 239 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-vhrm-5-849">23</xref>
###xml 763 765 763 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 1029 1031 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-vhrm-5-849">22</xref>
###xml 1032 1034 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47-vhrm-5-849">47</xref>
###xml 316 324 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
###xml 609 617 <span type="species:ncbi:9606">patients</span>
###xml 754 762 <span type="species:ncbi:9606">patients</span>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
###xml 900 908 <span type="species:ncbi:9606">patients</span>
###xml 1259 1267 <span type="species:ncbi:9606">patients</span>
Similarly to other studies we were not able to show any significant correlation between fractalkine levels and other classical risk factors for atherosclerosis, such as lipid metabolism (HDL-C, LDL-C, TC, and TG), age, BMI, or diabetes.22,23 In our study, fractalkine serum levels were not significantly elevated in patients who received CABG surgery within two weeks before attending rehabilitation. This indicates that the acute inflammatory phase in these patients has already subsided. Furthermore, fractalkine levels in patients with two or three occluded coronary arteries were not higher than those in patients with only one stenosed coronary artery. These data suggest that the differences in the inflammatory situations between controls and CHD patients,22 or as suspected here, between controls and diabetic patients are leveled by rehabilitation. Serum fractalkine levels are increased in patients with CHD during the acute inflammatory state of the disease, such as acute myocardial infarction or acute heart failure.22,47 After the acute phase of a cardiovascular inflammatory disease optimized medical treatment, such as that given during rehabilitation, may decrease the inflammatory status, as shown by the similar serum fractalkine levels in patients and healthy controls in this study.
###end p 38
###begin title 39
Conclusion
###end title 39
###begin p 40
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 138 142 <span type="species:ncbi:9606">IDDM</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 487 494 <span type="species:ncbi:9606">patient</span>
###xml 716 720 <span type="species:ncbi:9606">IDDM</span>
###xml 736 744 <span type="species:ncbi:9606">patients</span>
Our results demonstrate the relevance of optimized medical treatment, such as that given during rehabilitation, for patients with CHD and IDDM. The present data show that in CHD and diabetic patients, in whom an activated inflammatory state is expected, inflammation as determined by serum levels of fractalkine was at the control level. Even in an elevated inflammatory state caused by postprandial hyperlipemia, no significant increase in fractalkine serum levels was found in the two patient groups compared to control subjects. The results may be explained by the quiescent disease state, optimized anti-inflammatory treatment with statins, ACE inhibitors and ARBs, and the controlled environment of the CHD and IDDM rehabilitation patients.
###end p 40
###begin p 41
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Disclosures</bold>
Disclosures
###end p 41
###begin p 42
The authors report no conflicts of interest in this work. The technical assistance of Ms Claudia Pilowski and Ms Susanne Koch is gratefully acknowledged.
###end p 42
###begin title 43
References
###end title 43
###begin article-title 44
The pathogenesis of atherosclerosis - an update
###end article-title 44
###begin article-title 45
Inflammation in atherosclerosis
###end article-title 45
###begin article-title 46
Cytokines in atherosclerosis: pathogenic and regulatory pathways
###end article-title 46
###begin article-title 47
Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms
###end article-title 47
###begin article-title 48
Mast cells promote atherosclerosis by releasing proinflammatory cytokines
###end article-title 48
###begin article-title 49
###xml 44 49 <span type="species:ncbi:9606">human</span>
Detection of activated T lymphocytes in the human atherosclerotic plaque
###end article-title 49
###begin article-title 50
Adhesion molecules and atherosclerosis
###end article-title 50
###begin article-title 51
Chemokines-chemotactic cytokines that mediate inflammation
###end article-title 51
###begin article-title 52
Chemokines, leukocytes, and atherosclerosis
###end article-title 52
###begin article-title 53
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
Fractalkine: a new class of membrane-bound chemokine with CX3C motif
###end article-title 53
###begin article-title 54
Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion
###end article-title 54
###begin article-title 55
###xml 91 94 <span type="species:ncbi:10116">rat</span>
Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart
###end article-title 55
###begin article-title 56
The role of fractalkine in the recruitment of monocytes to the endothelium
###end article-title 56
###begin article-title 57
Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity
###end article-title 57
###begin article-title 58
###xml 55 60 <span type="species:ncbi:9606">human</span>
Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease
###end article-title 58
###begin article-title 59
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion
###end article-title 59
###begin article-title 60
Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation
###end article-title 60
###begin article-title 61
TLR signaling: An emerging bridge from innate immunity to atherogenesis
###end article-title 61
###begin article-title 62
A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection
###end article-title 62
###begin article-title 63
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease
###end article-title 63
###begin article-title 64
Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis--possible role in vascular inflammation
###end article-title 64
###begin article-title 65
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy
###end article-title 65
###begin article-title 66
Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis
###end article-title 66
###begin article-title 67
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease
###end article-title 67
###begin article-title 68
Diabetes and atherosclerosis: an overview
###end article-title 68
###begin article-title 69
Dietary factors that promote or retard inflammation
###end article-title 69
###begin article-title 70
Diabetes-enhanced inflammation and apoptosis: impact on periodontal pathosis
###end article-title 70
###begin article-title 71
The role of chemokines and chemokine receptors in diabetic nephropathy
###end article-title 71
###begin article-title 72
Leukocyte activation by triglyceride-rich lipoproteins
###end article-title 72
###begin article-title 73
###xml 74 79 <span type="species:ncbi:9606">human</span>
Nutritional lipid emulsions modulate cellular signaling and activation of human neutrophils
###end article-title 73
###begin article-title 74
Activation of leukocytes by postprandial lipemia in healthy volunteers
###end article-title 74
###begin article-title 75
Postprandial inflammation and endothelial dysfunction
###end article-title 75
###begin article-title 76
Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies
###end article-title 76
###begin article-title 77
###xml 121 126 <span type="species:ncbi:9606">human</span>
Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary artery
###end article-title 77
###begin article-title 78
###xml 41 46 <span type="species:ncbi:9606">human</span>
Proliferating or interleukin-1-activated human vascular smooth muscle cells secrete copious interleukin-6
###end article-title 78
###begin article-title 79
Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances interleukin-6 and MCP-1 production
###end article-title 79
###begin article-title 80
The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics
###end article-title 80
###begin article-title 81
Internal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factor
###end article-title 81
###begin article-title 82
New insights in preventive cardiology and cardiac rehabilitation
###end article-title 82
###begin article-title 83
Novel aspects of postprandial lipemia in relation to atherosclerosis
###end article-title 83
###begin article-title 84
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
###end article-title 84
###begin article-title 85
C-reactive protein-(CRP)-lowering agents
###end article-title 85
###begin article-title 86
###xml 73 81 <span type="species:ncbi:9606">patients</span>
CX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulators
###end article-title 86
###begin article-title 87
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study
###end article-title 87
###begin article-title 88
Effects of insulin and glucose on cytokine production from peripheral blood mononuclear cells
###end article-title 88
###begin article-title 89
Insulin enhancement of cytokine-induced coagulation/inflammation-related gene transcription in hepatocytes
###end article-title 89
###begin article-title 90
Cytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failure
###end article-title 90
###begin p 91
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 160 164 <span type="species:ncbi:9606">IDDM</span>
###xml 201 209 <span type="species:ncbi:9606">patients</span>
Fraktalkine levels in patients following rehabilitaiton are not higher than fractalkine levels in healthy control subjects. Blood samples of diabetic patients (IDDM; n = 47) and coronary heart disease patients (CHD; n = 46) following rehabilitation and blood samples of apparently healthy volunteers (Con; n = 50) were measured by fractalkine ELISA. Mean and standard error of the mean are presented. Significances are given above the columns.
###end p 91
###begin p 92
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
###xml 100 104 <span type="species:ncbi:9606">IDDM</span>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
Abbreviations: CHD, coronary heart disease; Con, control; ELISA, enzyme-linked immunosorbent assay; IDDM, insulin-dependent diabetic patients.
###end p 92
###begin p 93
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 918 919 918 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 963 964 963 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 987 988 987 988 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1213 1214 1213 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 158 162 <span type="species:ncbi:9606">IDDM</span>
###xml 171 179 <span type="species:ncbi:9606">patients</span>
###xml 998 1006 <span type="species:ncbi:9606">patients</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
Induction of postprandial hyperlipemia reduces fractalkine levels in healthy control subjects, but not in patients following rehabilitation. Blood samples of IDDM and CHD patients following rehabilitation and blood samples of healthy subjects (Con) were collected at time-point 0. Immediately thereafter a postprandial hyperlipemia was induced by a defined meal of 1,285 kcal/m2 body suface (105 g fat + 300 mg cholesterol + 48 g carbohydrates + 32 g protein. At two time-points later (four and eight hours, respectively) blood samples were taken and measured by fractalkine ELISA. Data are presented as a box blot (SigmaPlot). The whiskers and box lines indicate the 10th, 25th, median, 75th, and 90th percentiles. The broken line indicates the mean. Extra symbols indicate outliers. Analysis by one-way ANOVA showed a significant difference between the fractalkine levels at the time-points of the control subjects (P = 0.004), whereas levels for the diabetic (P = 0.080) and the CAD (P = 0.574) patients were not significantly different at the given time-points. Post-hoc analysis at the 0.01 level showed the same result; however, diabetic patients at the time-point 0 and 4 were different at the 0.05 level (P = 0.033).
###end p 93
###begin p 94
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
###xml 159 163 <span type="species:ncbi:9606">IDDM</span>
###xml 192 200 <span type="species:ncbi:9606">patients</span>
Abbreviations: ANOVA, analysis of variance; CAD, coronary artery disease; CHD, coronary heart disease; Con, control; ELISA, enzyme-linked immunosorbent assay; IDDM, insulin-dependent diabetic patients.
###end p 94
###begin p 95
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 85 90 <span type="species:ncbi:9606">Human</span>
Reduction in fractalkine levels in lipofundin-treated cultures of vessel wall cells. Human vascular smooth muscle cells (20,000 SMC/cm2) were cultured in 24-well plates. After 24 hours the medium was changed and fractalkine production induced by costimulation with interferon-gamma and tumor necrosis factor-alpha (200 U/ml, 20 ng/ml, respectively). Parallel cultures were incubated in the presence of various concentrations of lipofundin. After 24 hours, the supernatants were harvested and measured by fractalkine ELISA. Two experiments provided similar results.
###end p 95
###begin p 96
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: ELISA, enzyme-linked immunosorbent assay; SMC, smooth muscle cells.
###end p 96
###begin p 97
###xml 53 54 53 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="tfn1-vhrm-5-849">a</xref>
Characteristics of the investigated study populationsa
###end p 97
###begin p 98
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
###xml 7 15 <span type="species:ncbi:9606">Patients</span>
###xml 49 53 <span type="species:ncbi:9606">IDDM</span>
Notes: Patients with insulin-dependent diabetes (IDDM; n = 47) or coronary heart disease (CHD; n = 46) were compared to healthy controls (n = 50). Values are presented as mean +/- standard deviation;
###end p 98
###begin p 99
###xml 4 5 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The P-value for comparison between all three groups was calculated by ANOVA. The values of the categorical variables are compared by chi-squared test.
###end p 99
###begin p 100
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ANOVA, analysis of variance; BMI, body mass index; CHD-FH, family history of coronary heart disease.
###end p 100
###begin p 101
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="tfn4-vhrm-5-849">a</xref>
Classical markers of inflammation and lipid metabolisma
###end p 101
###begin p 102
###xml 0 6 0 6 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Notes:</bold>
###xml 7 15 <span type="species:ncbi:9606">Patients</span>
###xml 49 53 <span type="species:ncbi:9606">IDDM</span>
Notes: Patients with insulin-dependent diabetes (IDDM; n = 47) or coronary heart disease (CHD; n = 46) were compared to healthy controls (n = 50) at timepoint 0. Values are presented as mean +/- standard deviation;
###end p 102
###begin p 103
###xml 4 5 4 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The p-value for comparison between all three groups was calculated by ANOVA.
###end p 103
###begin p 104
###xml 0 14 0 14 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Abbreviations:</bold>
Abbreviations: CRP, C -reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol.
###end p 104

